Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

353.70 11.12 −3.05%
Market cap
$9.8B
P/E
42.5×
Fwd P/E
35.4×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(9.50%) 10.84% 2.50% 3.11%
Piotroski F-Score
5 5 7 5
ROA
(6.66%) 7.62% 1.75% 2.17%
ROIC
2.15% 0.41% 0.55% 0.49%
Return on Tangible Assets
(23.63%) 25.94% 6.61% 8.63%
Average Days of Receivables
66.32 65.08 60.07 62.28
Free Cash Flow per Share
12.51 13.74 13.26 13.20
Free Cash Flow
336.90 374.70 357.40 353.10
Capital Expenditures
(154.60) (157.50) (153.00) (139.50)
Other line items
Cash ROIC
3.60% 3.67% 3.72% 3.53%
Accounts Receivable Turnover
5.52 5.66 6.09 5.68
Accounts Payable Turnover
9.73 9.89 9.20 8.81
Inventory Turnover
1.54 1.66 1.60 1.58
Average Days of Payables
38.51 37.87 38.97 42.05
Days of Inventory on Hand
234.16 217.45 225.60 228.76
Tax Rate
(0.20) (0.24) (0.24) (0.37)
Research and Development Expense of Revenue
11.14% 0.00% 0.00% 10.29%
Selling, General and Administrative Expense of Revenue
32.35% 32.68% 32.74% 32.91%
Share Based Compensation of Revenue
0.00% 4.13% 0.00% 0.00%
Interest Coverage
4.57 0.96 1.17 1.09
Operating CF/Net income
(0.73) 0.70 3.02 2.21
Depreciation/Fixed assets
0.00 0.56 0.00 0.00
Capex/Depreciation
0.00 (0.52) 0.00 0.00
Revenue per Share
94.99 94.75 96.07 96.81
Operating CF per Share
18.26 19.52 18.93 18.42
Capex per Share
(5.74) (5.78) (5.68) (5.22)
Capex to Sales
0.06 0.06 0.06 0.05

Fold the line items

Columns are period end dates